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A major route of transmission of Visna/maedi virus (VMV), an ovine lentivirus, is thought to be via the
respiratory tract, by inhalation of either cell-free or cell-associated virus. In previous studies, we have shown
that infection via the lower respiratory tract is much more efficient than via upper respiratory tissues (T. N.
McNeilly, P. Tennant, L. Lujan, M. Perez, and G. D. Harkiss, J. Gen. Virol. 88:670–679, 2007). Alveolar
macrophages (AMs) are prime candidates for the initial uptake of virus in the lower lung, given their in vivo
tropism for VMV, abundant numbers, location within the airways, and role in VMV-induced inflammation.
Furthermore, AMs are the most likely cell type involved in the transmission of cell-associated virus. In this
study, we use an experimental in vivo infection model that allowed the infection of specific segments of the ovine
lung. We demonstrate that resident AMs are capable of VMV uptake in vivo and that this infection is associated
with a specific up-regulation of AM granulocyte-macrophage colony-stimulating factor mRNA expression (P <
0.05) and an increase in bronchoalveolar lymphocyte numbers (P < 0.05), but not a generalized inflammatory
response 7 days postinfection. We also demonstrate that both autologous and heterologous VMV-infected AMs
are capable of transmitting virus after lower, but not upper, respiratory tract instillation and that this transfer
of virus appears not to involve the direct migration of virus-infected AMs from the airspace. These results
suggest that virus is transferred from AMs into the body via an intermediate route. The results also suggest
that the inhalation of infected AMs represents an additional mechanism of virus transmission.
Visna/maedi virus (VMV) is a member of the lentivirus sub-
group of retroviruses that cause lymphoid interstitial pneumo-
nia, encephalitis, arthritis, and mastitis in sheep (40, 41). The
main routes of transmission of VMV are thought to be through
the ingestion of infected colostrum and/or milk or through the
inhalation of infected respiratory secretions (6, 34). We re-
cently have demonstrated that a major route of respiratory
transmission is likely via the uptake of cell-free VMV in the
lower respiratory tract (33), although the initial target cells for
cell-free VMV at this site were not identified.
It is known that VMV exhibits strong tropism for alveolar
macrophages (AMs) in vivo in naturally infected sheep (7, 9,
18, 30) and is present in AMs following experimental infection
from 11 days after lung instillation (19, 42). In addition, AMs
are present in large numbers within the lower lung airspace.
Consequently, AMs represent a likely initial target for VMV
uptake in the lower respiratory tract and therefore may play a
key role in the respiratory transmission of VMV.
Assuming AMs play a role in respiratory transmission of
VMV, virus taken up by resident AMs must be transmitted
from these cells within the lung airspace into the body. As yet
there is no information regarding the transfer of virus from
VMV-infected AMs in the airspace to adjacent lung tissue.
Transfer of virus from infected AMs also may be relevant with
regard to heterologous cell-associated virus transmission, as it
is possible that respiratory transmission is mediated by the
inhalation of both cell-free and cell-associated VMV derived
from infected individuals. However, as yet there is no direct
evidence that cell-associated virus transmission occurs between
sheep.
If virus transfer occurs from VMV-infected AMs in the
airspace entering into the body, it is likely to involve the in-
fection of the draining lymph nodes, which are thought to be
important initial sites of infection (5). This transfer may in-
volve an indirect route or may occur by direct migration of
infected AMs to the lymph node, as there is evidence to sug-
gest that AMs are capable of migrating from the alveolar space
into the regional lymphoid tissue (12, 23, 27).
AMs also have been implicated as the main cell type in-
volved in VMV-induced lung inflammation, primarily by the
dysregulation of cytokine gene expression and subsequent re-
cruitment of inflammatory cells (29, 50). It is possible that AMs
mediate a similar inflammatory response during early VMV
infection in vivo, as suggested by the observed up-regulation of
interleukin-8 (IL-8) expression by AMs within 48 h of in vitro
infection (28). This may have implications for the enhance-
ment of virus uptake, as a number of proinflammatory cyto-
kines have been shown to enhance VMV replication in AMs
and other macrophages in vitro (15, 50), and generalized in-
flammation is likely to result in the recruitment of VMV target
cells, namely, macrophages and dendritic cells (DCs) (7, 36).
In this study, we investigated the role of AMs in initial VMV
uptake using a segmental lung model system. We demonstrate
that AMs are capable of the uptake of cell-free virus in vivo
and that early VMV infection is associated with a specific
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up-regulation of AM granulocyte-macrophage colony-stimu-
lating factor (GM-CSF) mRNA expression in the absence of a
generalized inflammatory response. Furthermore, we demon-
strate that both autologous and heterologous VMV-infected
AMs are capable of transmitting virus into the body after
instillation into the lower lung, and that the transfer of virus
from AMs in the lower lung to regional lymph nodes appears
not to involve AM migration.
MATERIALS AND METHODS
Virus propagation and titration. Low-passage VMV strain EV1 (38) was
propagated and titrated on ovine skin cells (OSCs) as described previously (33).
Mock-infected medium controls were generated by culturing the same OSCs as
those used for virus propagation, but without the addition of virus. Supernatants
were collected on the same day as viral supernatants and processed identically.
BAL. Bronchoalveolar lavage (BAL) was performed either under general
anesthesia or at postmortem as described previously (11). Lavage fluid subse-
quently was centrifuged at 400  g for 7 min, and the resultant cell pellets were
resuspended in sterile phosphate-buffered saline (PBS). Cells were counted using
a Neubauer hemocytometer before cytocentrifuge preparation, AM purification,
and VMV infection.
Differential cytology of BAL cells. Cytocentrifuge slides were stained using
Leishman’s stain, and differential cell counting was performed on 500 cells. Cells
were classified as macrophages, neutrophils, lymphocytes, eosinophils, mast cells,
or other cells according to standard morphological criteria. Total numbers of
BAL cells/milliliter of BAL fluid and the percentage of each cell type within the
BAL cell population were compared to previously published normal limits (11).
Purification of AMs and RNA extraction. The purification of AMs was based
on a procedure described previously (28, 50) that relies on the preferential
adherence of macrophage populations to tissue culture flasks. After pelleting and
counting BAL cells, cells were resuspended in 7 ml RMPI 1640 medium (In-
vitrogen, Paisley, United Kingdom) containing 10% fetal calf serum (FCS), 2
mM L-glutamine, 50 g/ml penicillin, 50 g/ml streptomycin, 2 g/ml ampho-
tericin B, and 0.05 M -mercaptoethanol and were seeded into 25-cm2 tissue
culture flasks. After 2 h of incubation at 37°C with 5% CO2, nonadherent cells
were removed by washing with PBS. This purification method consistently re-
sulted in 96 to 98% pure populations of AMs, as determined by morphological
assessment and CD14 staining of cytocentrifuge preparations during preliminary
experiments. Adherent cells were trypsinized, washed once with 7 ml fresh
medium, and resuspended in 350 l RLT buffer (Qiagen, Crawley, United
Kingdom) containing 1% (vol/vol) -mercaptoethanol. Total RNA extraction
then was carried out using the RNeasy mini kit (Qiagen), including on-the-
column digestion of DNA with RNase-free DNase (Qiagen), by following the
manufacturer’s instructions for animal cells.
RNA extraction from animal tissue. Samples of either lung parenchyma (1
cm3) or lymph node (0.5 cm3) were collected postmortem and stored in RNA-
later (Qiagen) at 80°C prior to RNA extraction using the Fastprep cell dis-
rupter system (Bio 101 Thermoelectron; Qbiogene, Cambridge, United King-
dom). Samples of lung parenchyma (100 mg) or lymph node (20 mg) in 1 ml RLT
buffer (Qiagen) containing 1% (vol/vol) -mercaptoethanol were placed in a
2-ml Eppendorf tube containing lysis matrix D (Qbiogene) and pulsed in a
Fastprep machine for 40 s. Supernatants then were passed through a Qiashred-
der column (Qiagen), and total RNA was extracted using the RNeasy mini kit,
including on-the-column digestion of DNA with RNase-free DNase (Qiagen), by
following the manufacturer’s instructions for animal tissues.
Real-time RT-PCR quantitation of AM cytokine gene expression and VMV gag
RNA. The relative quantitation of cytokine gene expression and VMV RNA by
two-step real-time reverse transcription-PCR (RT-PCR) was performed using
the standard curve method. To generate VMV gag RNA standard curves, serial
dilutions of plasmid pDS1-gag containing the whole VMV strain EV1 gag gene
(provided by Heide Niesalla, University of Edinburgh) were amplified. To gen-
erate plasmids for cytokine and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) standard curves, RNA was extracted from in vitro VMV-infected
AMs and cDNA was constructed using Superscript II (Invitrogen) and anchored
oligo(dT) primers (Sigma) according to the manufacturer’s instructions. External
primers spanning 300 to 500 bp were used to generate primary PCR products.
PCR was carried out with Hot Taq DNA polymerase (Biogene, Kimbolton,
United Kingdom) according to the manufacturer’s recommendations and using
3 l cDNA and 25 pmol of each primer. Primer sequences and annealing
temperatures are shown in Table 1.
PCR products were purified using the S.N.A.P. UV-free gel purification kit
(Invitrogen) and subsequently cloned into the sequencing vector pCR2.1-TOPO
(Invitrogen) according to the manufacturer’s instructions. Aliquots of each plas-
mid were sequenced to confirm the presence of the correct insert.
Real-time PCR was performed on cDNA samples using a RotorGene 3000
real-time thermal cycler (Corbett Research, Sydney, Australia) and the appro-
priate internal primer sets (Table 1). Cycling was performed in 20-l reaction
volumes containing 1 l cDNA, 10 l of 2Quantitect SYBR green PCR master
mix (Qiagen), and 0.5 M of each primer. Thermal cycling parameters involved
a 15-min preincubation at 95°C followed by 40 cycles of denaturation at 94°C for
20 s, primer annealing at 52 to 57°C for 20 s, and extension at 72°C for 20 s.
Fluorescence data acquisition was performed after each extension step.
Following amplification, a plot of the fluorescence versus the cycle number was
generated. The threshold value for each sample was calculated automatically by
the RotorGene software (version 5.10) using the fit-point method. Serial 1:10
dilutions of plasmid containing the gene of interest ranging from 108 to 102
copies per l were run in parallel with each series of samples, allowing the
automatic generation of a standard curve by the RotorGene software. The
correlation coefficients of standard curves were between 0.98 and 0.99, and PCR
efficiencies calculated from the slopes were 90%. The number of copies per
microliter of sample then was calculated for each sample and results were
normalized to GAPDH, the expression of which had previously been shown to be
unaffected by VMV infection. Standards were run in triplicate, and samples were
run in duplicate. Melting curve analysis was performed at the end of each PCR
run to verify the specificity of the PCR product.
Immunocytochemistry and histopathology. Selected lung lobes were inflated
with a 1:1 mixture of OCT compound (Tissue-Tek; Sakura-Finetek, Zoeter-
woude, The Netherlands) before being cut into 1-cm3 blocks and snap-frozen in
isopentane-dry ice. Tissue sections were cut to 6 m thick, mounted on poly-L-
lysine-coated slides (BDH, Poole, United Kingdom), and stored at 80°C prior
to use.
Immunocytochemical staining was performed on tissue sections and cytocen-
trifuge slides as previously described (32) using the EnVision Plus HRP system
(DakoCytomation, Ely, United Kingdom). Details of monoclonal antibodies
(MAbs) used in this study are provided in Table 2. Cell counts were expressed as
the number of positively stained cells per millimeter of bronchiolar epithelium
for airways and the number of positively stained cells per square millimeter of
lung tissue for lung parenchyma (determined by stereology).
For histopathological analysis, appropriate tissue sections were stained with
hematoxylin and eosin. Samples were analyzed blindly by a trained histopathol-
ogist, and descriptive qualitative comments on each slide were provided.
Ex vivo infection of AMs with VMV. Immediately after collection, BAL cells
were incubated in RMPI 1640 medium (Invitrogen) containing 2 mM L-glu-
tamine and 10% FCS with 1 50% tissue culture infectious dose (TCID50)/cell
VMV strain EV1 in VueLife 7 tissue culture bags (Cellgenix, Freiburg, Ger-
many) for 2 h. Cell suspensions then were centrifuged at 400  g for 5 min and
resuspended in 25 ml PBS. Cell pellets were washed a further five times in PBS
before finally being resuspended in an appropriate volume of PBS. Prior to
instillation, viable cell counts were performed using trypan blue exclusion, and
differential cytology revealed cell populations to be between 90 and 95% AMs.
Aliquots of the last wash were stored at 80°C for subsequent virus titration to
confirm the absence of cell-free virus.
Respiratory tract instillation of cell-free VMV and VMV-infected AMs. For
upper respiratory tract instillations of VMV-infected AMs, 1  106 cells were
resuspended in 2 ml PBS, and 1 ml was instilled into each nostril using a modified
8F portex intravenous catheter (Sims Portex Ltd., Hythe, United Kingdom),
which resulted in the exposure of the nasal cavity and nasopharynx to instillates,
and was shown not to affect AM viability.
Lower respiratory tract instillations of free virus or virus-infected AMs were
performed under general anesthesia and delivered via a 21-gauge polyethylene
catheter inserted into the lateral channel of a flexible fiber optic bronchoscope
(5.3 mm outer diameter) (model FG-16X; Pentax, Englewood, CO). For instil-
lations of cell-free VMV, 2-ml volumes containing 1  106 TCID50 VMV were
delivered endoscopically into the left cardiac lung lobe. At the same time, an
equivalent volume of mock-infected medium control was instilled into a right
cardiac lung lobe. For the instillation of VMV-infected AMs, 1  106 cells in 2
ml PBS were delivered into either the left or right cardiac lung lobes as required,
and donor AMs were harvested from either the right or left caudodorsal lobe.
Detection of VMV-specific provirus, transcripts, and serum antibodies. VMV
proviral gag DNA in peripheral blood mononuclear cells (PBMCs) was detected
by seminested PCR (snPCR) as described previously (33). Spliced viral tran-
scripts of rev and env genes were detected by RT-snPCR.
For the detection of rev gene transcripts, snPCR of cDNA samples was per-
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formed using the first-round primer pair rev 1 (sense, CAG AGT AAC CTG
GAC AGA CA) and rev 3 (antisense, TAT CTG GGT AAA AGT GCG CC) and
the second-round primer pair rev 1 and rev 2 (antisense, GTT TTT CCT CGA
GGT CCA CA). Both the first- and second-round primer pairs spanned the rev
internal splice site of VMV strain EV1 (nucleotide position 6129; accession no.
S51392) and generated PCR products of 272 and 189 bp, respectively. RT-
snPCR detection of env gene transcripts was performed using the first-round
primer pair env 1 (sense, AGA GAA GCG ACG AAA GGA CC) and env 3
(antisense, CCA TTT TTC ACA TGG TTC CC) and the second-round primer
pair env 1 and env 2 (antisense, TAC CTG TTA CCA AGC CCT GC). The first-
and second-round primer pairs spanned the major splice donor site of EV1
(nucleotide position 319; accession no. S51392). Due to alternative splicing at the
5 end of the env gene transcripts, two PCR products were generated for both
first-round (354 and 399 bp) and second-round (263 and 308 bp) reactions
(accession nos. AM501483 and AM501484, respectively).
PCR was carried out using Hot Taq DNA polymerase (Biogene) and 25 pmol of
each primer. Five microliters of cDNA was added to first-round reactions, and a 3-l
aliquot from the first round of PCR was used in the second-round reaction. First-
and second-round reactions involved 15 and 35 cycles of amplification, respectively.
VMV-specific antibodies in serum were detected using a commercial enzyme-
linked immunosorbent assay (ELISA) kit (ELITEST-MVV/CAEV; Hyphen
Biomed, Neuville sur Oise, France) (37).
Fluorescent labeling of VMV-infected AMs with PKH26 dye. Cells were fluo-
rescently labeled using a PKH26 red fluorescence cell-linker kit (Sigma, St.
Louis, MO) according to the manufacturer’s instructions. Prior to the use of
labeled cells, viable cell counts were performed using trypan blue exclusion, and
a cytocentrifuge preparation of an aliquot of the stained cells was analyzed using
TABLE 1. Primer sequences and annealing temperatures for real-time PCR assays
Gene product
(reference)
GenBank
accession no. Primer type Primer sequence
b (533) Productsize (bp)
Annealing
temp (oC)
GAPDHa AF030943 External F, AAG GCA GAG AAC GGG AAG 366 55
R, AGT GAT GGC GTG GAC AGT
Internal F, GGT GAT GCT GGT GCT GAG TA 265 57
R, TCA TAA GTC CCT CCA CGA TG
GM-CSFa NM_001009805 External F, GCC TGC TTC ACT TCT GGA C 425 55
R, GCT TCT CCT GGG CAC TGT
Internal F, GAT GGA TGA AAC AGT AGA AGT CG 261 57
R, CAG CAG TCA AAG GGA ATG AT
Tumor necrosis X55152 External F, TCC TTG GTG ATG GTT GGT 525 58
factor alphaa R, CAC TGA CGG GCT TTA CCT C
Internal F, GAA TAC CTG GAC TAT GCC GA 238 57
R, CCT CAC TTC CCT ACA TCC CT
Tumor growth factor NM_001009400 External F, GCC CTG GAC ACC AAC TAC TG 338 61
1 (49) R, TCA GCT GCA CTT GCA GGA G
Internal F, GAA CTG CTG TGT TCG TCA GC 169 55
R, GGT TGT GCT GGT TGT ACA GG
IL-1a NM_001009465 External F, CTG TGT TCT TCC CTT CCC TT 518 55
R, CAA AAA TCC CTG GTG CTG
Internal F, CCT TGG GTA TCA GGG ACA A 317 57
R, TGC GTA TGG CTT TCT TTA GG
IL-6 (14) NM_001009392 External F, GCT TCC AAT CTG GGT TCA 347 55
R, CCA CAA TCA TGG GAG CCG
Internal F, TCC AGA ACG AGT TTG AGG 236 52
R, CAT CCG AAT AGC TCT CAG
IL-8 NM_001009401 External F, GAA GTC CTC TGG GAC AGC AG 429 55
R, TTG GAA GCA ATG GAA AAA GG
Internal F, ATG AGT ACA GAA CTT CGA 222 55
R, TCA TGG ATC TTG CTT CTC
IL-10 (14) NM_001009327 External F, AGC TGT ACC CAC TTC CCA 305 55
R, GAA AAC GAT GAC AGC GCC
Internal F, TGA AGG ACC AAC TGA ACA GC 160 55
R, TTC ACG TGC TCC TTG ATG TC
IL-12p40a AF209435 External F, CTG CTG CTT TTG ACA CTG AA 452 54
R, CTG GTT TTC CCT GGT TTT G
Internal F, TCA GAC CAG AGC AGT GAG GT 243 57
R, GCA GGT GAA GTG TCC AGA AT
IL-18a NM_001009263 External F, TCA GAT CAC GTT TCC TCT CC 348 55
R, GAT GGT TAC AGC CAG ACC TC
Internal F, GAG CAC AGG CAT AAA GAT GG 241 57
R, TGA ACA GTC AGA ATC AGG CAT A
VMV Gag S51392 Internal F, TAG AGA CAT GGC GAA GCA AGG CT 462 55
R, TCC TGC TTG CAA ATT TAC AAT AGG
a Primers were kindly donated by Katie Matthews, University of Edinburgh.
b F, forward (sense) primer; R, reverse (antisense) primer.
TABLE 2. Details of MAbs used in immunocytochemical stainingc
MAb Specificity (reference) Cellular expression (reference)
SW 73.2a MHC II DCs, B cells, activated T cells,
macrophages (25)
CC20b CD1b DCs including RTDCs, cortical
thymoctes (26, 32)
17Db CD4 T-helper cells (31)
SBU-T8b CD8 T-cytotoxic cells (31)
VPM67a CD14 Monocytes, macrophages (21)
VPM70 VMV p25 capsid protein
(35)
NA
a Kindly donated by Professor John Hopkins, University of Edinburgh.
b Kindly donated by Ian Anderson, Moredun Research Institute.
c CD, cluster designation; MHC II, major histocompatibility complex class II;
NA, not applicable.
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an MPV II fluorescence microscope (Leitz, Wetzlar, Germany) to assess the
intensity and uniformity of staining.
Detection of PKH26-labeled cells. The detection of PKH26-labeled cells after
in vivo lung instillation was performed using fluorescence microscopy. At post-
mortem, BAL was performed on appropriate lung segments, and samples of lung
tissue and lymph nodes were collected. Cytocentrifuge slides of BAL cells and
sections of lung tissue and lymph nodes were fixed for 5 min in 4% paraform-
aldehyde in PBS at room temperature. Slides were washed twice in PBS for 3 min
each before incubation in 0.5 M glycine in PBS for 5 min at room temperature.
After two further PBS washes, slides were incubated in SYBR green (Roche,
Mannheim, Germany) diluted 1:20,000 in PBS for 5 min. After a final PBS wash,
slides were mounted in Mowiol mounting medium (Calbiochem-Novabiochem,
San Diego, CA) and allowed to set for 1 h at room temperature before micro-
scopic analysis using an MPV II fluorescence microscope (Leitz). For cytocen-
trifuge preparations, a total of 1,000 cells was counted, and the number of
PKH26-positive cells was recorded. For tissue samples, a total of 10 sections cut
at 100-m intervals was analyzed per sample, and the location of positive cells
was recorded.
Sheep. Six Blackface ewes were used to assess the in vivo uptake of cell-free
VMV by AMs and subsequent lung inflammatory responses. Suffolk-cross ewes
were used to assess both the infectivity of AM-associated VMV in vivo (n  7)
and the migration of VMV-infected AMs after lower lung instillation (n 7). All
sheep were commercially sourced, determined to be free from VMV provirus,
and seronegative for VMV-specific antibodies prior to use. All experimental
procedures involving animals were approved by The University of Edinburgh’s
Biological Services Ethical Review Committee and were performed under li-
cense as required by the United Kingdom’s Animals (Scientific procedures) Act
1986.
Statistical analysis. Data were analyzed for normality of distribution using the
Kolmogorov-Smirnov and Anderson-Darling tests. Real-time PCR data, BAL
cytology, and immunocytochemical cell counts all were normally distributed, and
therefore statistical analyses were performed using paired t tests. P values
of 	0.05 were considered significant.
RESULTS
Uptake of cell-free VMV by AMs in vivo. The lung was
classified into various anatomical segments, as shown in Fig. 1,
to allow multiple treatments within the same animal and to
provide within-animal control samples. This segmental ap-
proach for VMV lung instillation has been described previ-
ously (17, 42). To evaluate the uptake of cell-free VMV by
resident lung AMs, 1 106 TCID50 of VMV were instilled into
the left cardiac lung lobe of six sheep, and at the same time an
equivalent volume of mock-infected medium was instilled into
the right cardiac lobe. AMs from virus-treated, mock-treated
lung lobes and a naive lung lobe (right caudodorsal) were
harvested by BAL 7 days postinstillation. Following AM puri-
fication, cells were analyzed for the presence of VMV RNA by
real-time RT-PCR. Baseline AMs harvested from the relevant
lung lobes 7 days preinstillation also were analyzed. Viral gag
RNA was detected in AMs from virus-treated lung lobes in all
six sheep, with values ranging from 1,000 to 66,000 copies/l
cDNA. No viral RNA was detected in AMs purified from
mock-infected or nontreated control lung lobes or in AMs
purified prior to virus instillation (Fig. 2A). GAPDH was de-
tected in all cDNA samples, indicating that RNA extraction
and RT were successful for all samples analyzed (data not
shown). No dissemination of virus from the virus-treated lung
lobes to control lobes was observed 7 days postinfection, vali-
dating the segmental approach to VMV lung instillation used
in this study.
Spliced viral gene transcripts of both rev and env genes
(expressed early and late in the VMV life cycle, respectively
[39]) were detected by RT-snPCR of AMs obtained from virus-
treated lung lobes in all sheep. For rev PCRs, two PCR prod-
ucts of approximately 190 and 270 bp were generated in all AM
samples and positive control cDNA (generated from in vitro-
FIG. 1. Diagram of the ovine lung indicating the location of lung
segments used for the delivery of multiple treatments and the provi-
sion of control samples within the same sheep. LC, left cardiac lung
lobe; RC, right cardiac lung lobe; LCD, left caudodorsal lung lobe;
RCD, right caudodorsal lung lobe.
FIG. 2. PCR detection of VMV RNA in purified AMs obtained
from VMV-treated (VMV), mock-treated (Mock), and untreated (Na-
ı¨ve) lung lobes of six adult Blackface ewes 7 days pre- and postinstil-
lation. (A) Detection of VMV gag RNA in AMs by real-time RT-PCR.
(B) Detection of VMV rev transcripts in AMs obtained from virus-
treated lung lobes by RT-snPCR. (C) Detection of VMV env tran-
scripts in AMs obtained from virus-treated lung lobes by RT-snPCR.
pre, preinstillation; post, postinstillation; , positive control (cDNA
from in vitro-infected OSCs); , negative control.
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infected OSCs), corresponding to first- and second-round PCR
products (Fig. 2B). Interestingly, env PCR analysis of AM
cDNA resulted in the generation of two PCR products of 263
and 308 bp in size, whereas the amplification of positive control
cDNA produced only the smaller env PCR product (Fig. 2C).
The two env transcripts differed by a 45-bp insert located 3 to
the RNA polymerase II binding site and 5 to the start of
translation (data not shown). Immunocytochemistry failed to
detect any viral capsid protein expression. Therefore, it is con-
cluded that AMs are capable of the uptake of cell-free VMV in
vivo and support virus replication to at least the level of late
viral gene transcription.
Assessment of lung inflammatory responses during early
VMV infection in vivo. We hypothesized that local inflamma-
tory responses influence initial virus uptake within the lung,
either by modulating virus replication within infected cells or
by the recruitment of VMV target cells. Following lower lung
instillation of 1  106 TCID50 of cell-free VMV strain EV1,
virus was detected in the blood from 2 to 3 weeks postinstilla-
tion (33). Therefore, key events involved in virus uptake from
the lung airspace are likely to occur during this initial 2- to
3-week period. For this reason, lung inflammation was assessed
at 7 days postinstillation, a time point within the previremic
stage of VMV infection.
BAL cells and lung tissue samples from virus-treated, mock-
treated, and naı¨ve lung lobes generated from the above ex-
periment were analyzed using a combination of real-time
RT-PCR, cytology of BAL cells, histopathology, and immuno-
cytochemistry. BAL cell populations were analyzed 7 days pre-
treatment and 7 days posttreatment; lung tissue was analyzed
at 7 days posttreatment. As no dissemination of virus from
virus-treated lung lobes was evident at 7 days posttreatment, a
direct comparison between inflammatory responses in virus-
treated and control lung lobes could be made for each indi-
vidual sheep, thus allowing paired statistical analyses of data.
Real-time RT-PCR analysis of cytokine mRNA expression
was performed on purified AM populations obtained from
VMV-treated, mock-treated, and naı¨ve lung lobes. The results
of the analysis of AM cytokine mRNA expression 7 days post-
treatment are shown in Fig. 3. The level of GM-CSF mRNA
expression was significantly up-regulated in AMs obtained
from virus-treated lung lobes compared to those of AMs from
both mock-treated (P 	 0.05) and naı¨ve lung lobes (P 	 0.05)
7 days postinstillation (Fig. 3I). A significant increase in IL-8
FIG. 3. Real-time RT-PCR analysis of cytokine mRNA expression in AMs obtained from VMV-treated (VIRUS), mock-virus treated
(MOCK), and untreated (NAI¨VE) lung lobes of six adult Blackface ewes 7 days postinstillation. Lines connect measurements in the three different
lung lobes in the same sheep. a, significant difference compared to the value for untreated lung lobes (P 	 0.05; paired t test); b, significant
difference compared to the value for mock-treated lung lobes (P	 0.05; paired t test). Symbols: F, sheep 301; Œ, sheep 303; f, sheep 328; E, sheep
348; ‚, sheep 413; , sheep 450.
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mRNA expression was observed in AMs from virus-treated
lung lobes compared to that of AMs from naı¨ve lobes (P 	
0.05) (Fig. 3C). However, no significant difference in IL-8
expression was observed between AMs obtained from virus-
treated and mock-treated lobes. No significant differences in
mRNA expression of IL-1, IL-6, IL-10, IL-12p40, IL-18, tu-
mor necrosis factor alpha, or tumor growth factor 1 were
observed between AMs from VMV-treated and mock-treated
or naı¨ve lobes. An analysis of cytokine gene expression in
pretreatment AM samples and posttreatment lung tissue did
not identify any significant differences between virus-treated
and control lung lobes (data not shown).
Total BAL cell numbers were within normal limits for all
pre- and posttreatment samples, and no significant differences
in total cell numbers were observed between lung lobes. The
percentages of lymphocytes within posttreatment BAL sam-
ples were significantly increased (P 	 0.05) in BAL samples
from VMV-treated lung lobes compared to those of BAL
samples from posttreatment mock-treated and naı¨ve lung
lobes, and they were above normal limits (13.6% 
 4.7%
[means 
 standard deviations]; normal limits, 3.1% 
 2.0%).
The percentages of all other cell types in posttreatment BAL
samples and all cell types in pretreatment BAL samples were
within normal limits, with no significant differences observed
between lobes.
No significant histopathological changes were identified in
any lung lobe evaluated. Immunocytochemical analysis of lung
tissue failed to identify any significant differences in the num-
bers of airway or parenchymal major histocompatibility com-
plex class II, CD1b, CD4, CD8, or CD14 cells between
virus-treated, mock-treated, and naı¨ve lung lobes (data not
shown).
Infectivity of AM-associated VMV in vivo. To determine
whether AM-associated VMV are infectious in vivo, autolo-
gous or heterologous VMV-infected AMs were instilled into
either the lower lung or the upper respiratory tract of sheep,
and the time taken for viremia and seroconversion to occur was
recorded. For lower lung instillations, AMs were harvested
from the right caudodorsal lung lobes of two donor Suffolk-
cross ewes by BAL and subsequently infected with VMV ex
vivo. Cells (1  106) were reinstilled into the left cardiac lung
lobes of the two donor sheep (autologous instillation), and an
identical number of cells were instilled into the same lobe of
two further Suffolk-cross ewes (heterologous instillation). For
upper respiratory tract instillations, AMs harvested from the
right caudodorsal lung lobe of a Suffolk-cross ewe at postmor-
tem subsequently were infected with VMV ex vivo, and 1 106
cells were instilled into the upper respiratory tract (n  2) or
left cardiac lung lobe (n  1) of heterologous Suffolk-cross
ewes. No virus was detected in samples of the final cell washes
prior to instillation, implying that washing had removed viable
cell-free VMV. To confirm the successful ex vivo infection of
instilled cells, aliquots of each VMV-infected AM preparation
were cultured in vitro for 1 week. VMV titers of in vitro culture
supernatants 7 days postinfection ranged from 1.1  105 to
4.0  106 TCID50/ml (Table 3), and VMV capsid protein was
detected exclusively within AM-like cells from all cultures 7
days postinfection (data not shown), indicating successful ex
vivo infection. All sheep were bled weekly up to 6 months
postinstillation, and blood samples were analyzed for the pres-
ence of VMV provirus and anti-VMV antibodies.
The times taken for viremia and seroconversion to occur for
each instillation are summarized in Table 3. Lower lung instil-
lation of autologous VMV-infected AMs resulted in the de-
tection of provirus at 2 weeks postinstillation and seroconver-
sion at 2 to 7 weeks postinstillation. Lower lung instillation of
heterologous VMV-infected AMs resulted in the detection of
provirus at 2 to 11 weeks postinstillation (mean, 3.6 weeks) and
seroconversion at 3 to 17 weeks postinstillation (mean, 7.6
weeks). The same heterologous VMV-infected AM prepara-
tion that resulted in successful infection after lower lung in-
stillation failed to result in viremia or seroconversion following
upper respiratory tract instillation by 6 months postinstillation.
Thus, both autologous and heterologous VMV-infected AMs
are infectious in vivo after lower lung instillation. The infec-
tivity of VMV-infected AMs after upper respiratory tract in-
stillation was not demonstrated.
Tracking of VMV-infected AMs after lower lung instillation.
The presence of provirus in blood cells following lung instilla-
tion of VMV-infected AMs indicated that virus was transferred
from AMs in the lung airspace into the body. The mechanism
of this virus transfer is unclear. However, it is likely that virus
entry involves the infection of draining lymph nodes, which are
thought to be an important site of initial infection prior to
dissemination throughout the body via the blood (5).
To determine whether VMV transfer from lung airspace to
TABLE 3. Summary of weekly PCR and ELISA results for detection of VMV infection after in vivo instillation of VMV-infected AM
Sheep no. Instillation routea VMV-AM prepna
Titer of VMV-AM in vitro
(TCID50/ml)b on day:
Wks to PBMC
being PCR
positivec
Wks to serum
being ELISA
positivec0 (last wash) 7 (supernatant)
1675 Lower lung Autologous (A) 0 1.1  105 2 2
1676 Lower lung Heterologous (A) 0 1.1  105 2 3
1677 Lower lung Autologous (B) 0 2.0  105 2 7
1678 Lower lung Heterologous (B) 0 2.0  105 2 3
5797 Lower lung Heterologous (C) 0 4.0  106 11 17
5798 Nasal Heterologous (C) 0 4.0  106 26 26
5800 Nasal Heterologous (C) 0 4.0  106 26 26
a AMs infected with VMV ex vivo were instilled into the left cardiac lung lobe (lower lung) or upper respiratory tract (nasal) of autologous and/or heterologous sheep.
(A), (B), and (C) refer to three separate VMV-infected AM preparations.
b Aliquots of VMV-infected AMs were cultured for 7 days, and VMV titers of the last washes and day 7 supernatants were calculated.
c Values are expressed as the number of weeks postinstillation for a positive result to occur.
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draining lymph nodes is mediated by the direct migration of
virus-infected AMs, ex vivo-infected AMs harvested from the
right caudodorsal lung lobes of four donor Suffolk-cross sheep
were labeled with the fluorescent dye PHK26. Labeled and
infected cells (1  106; 88 to 93% AMs) subsequently were
reinstilled into the airspace of the left cardiac lung lobes of
the four donor sheep (autologous instillations) and another
three Suffolk-cross sheep (heterologous instillations). To
allow for analysis at an additional time point, cell instilla-
tions were performed 7 days later in three of the seven
sheep (two autologous and one heterologous instillation),
with cells (91 to 94% AMs) for the second instillations
harvested from the left caudodorsal lung lobe and instilled
into the right cardiac lung lobe.
Postmortems were performed on sheep 8 days after the first
instillation, and the locations of PKH26-labeled cells within the
lung and draining lymph nodes (tracheobronchial and medias-
tinal) were determined using fluorescence microscopy. This
protocol therefore allowed the tracking of labeled AMs at 8
days postinstillation in all sheep and in three sheep at both 24 h
and 8 days postinstillation. A naı¨ve lung lobe (left caudodorsal)
and a nondraining lymph node (popliteal lymph node) from
each sheep were analyzed in parallel as negative controls. A
cytological analysis of BAL cell populations was performed,
and samples from six of seven sheep were analyzed for the
presence of VMV using snPCR and immunocytochemistry.
Postmortem PBMCs and serum samples were analyzed for the
presence of provirus and VMV-specific antibodies by snPCR
and ELISA, respectively.
The results are summarized in Table 4. Total numbers of
cells ranged from 2.6 105 to 1.6 107 cells/ml BAL fluid, and
results of differential cytology were within normal limits for all
BAL samples (data not shown). For the three sheep instilled at
two separate time points, cell numbers in 24-h- and 8-day-
postinstillation BAL samples were similar for individual sheep.
This suggested that no significant cell recruitment had oc-
curred into the bronchoalveolar compartments postinstillation
and that the percentage of PKH26 cells within 24-h and 8-day
BAL cell populations could be compared directly. Positive cells
were detected in all postinstillation BAL samples by fluores-
cence microscopy and generally exhibited typical AM mor-
phology (Fig. 4A, B). No differences in the distribution or
intensity of fluorescence staining of positive cells were ob-
served between 24-h-postinstillation samples, 8-day-postinstil-
lation samples, or stained cells prior to instillation. The per-
centage of PKH26 cells within BAL cell populations ranged
from 0.9 to 2.5%, and the percentages of PKH26 cells within
24-h- and 8-day-postinstillation BAL samples were similar for
individual sheep (Table 4). PKH26 cells were present in lung
tissue sections and were located within the alveolar airspaces
or within the lumen of small and large bronchioles (Fig. 4C,
D). No PKH26 cells were seen in negative control lung lobes
or in any of the lymph nodes, and no differences in the number
or location of PKH26 cells were detected between autologous
and heterologous instillations. In a further attempt to identify
PKH26-labeled cells within the draining lymph nodes, fluores-
cence-activated cell sorting was performed on the disaggre-
gated lymph nodes of sheep W48 and O61 to identify highly
fluorescent cells of the same size and complexity as AMs. An
analysis of 3  106 cells from each lymph node failed to
identify any positively labeled cells (data not shown).
The results of snPCR analysis of BAL samples and lymph
nodes also are shown in Table 4. VMV provirus was detected
in BAL samples from instilled lung lobes but not from negative
control lung lobes. Proviral gag DNA was detected in the
tracheobronchial lymph nodes of two out of three sheep in-
stilled with autologous AMs and one of three sheep instilled
with heterologous AMs, but not in mediastinal or the popliteal
lymph nodes. Immunocytochemical analysis for VMV capsid
protein was negative for all lung tissue, lymph nodes, and BAL
cells (not shown). No proviral DNA was detected in postmor-
tem PBMC samples, and no VMV-specific antibodies were
detected in postmortem serum samples.
These results indicate that virus was transferred from in-
fected AMs within the airspace to the tracheobronchial lymph
nodes within the first 8 days postinstillation. Furthermore,
there was no evidence that infected AMs migrated from the
airspace to the draining lymph nodes within this time period,
suggesting that this transfer of virus occurred independently of
direct cell migration.
DISCUSSION
In this study, it was shown that AMs are capable of the
uptake of cell-free VMV after lower lung instillation in vivo.
Furthermore, it was demonstrated that autologous VMV-in-
fected AMs are capable of efficiently transmitting virus from
TABLE 4. Postmortem analysis for the presence of PKH26-labeled cells and VMV provirus following lower lung instillation of autologous
and heterologous VMV-infected, PKH26-labeled bronchoalveolar cellsa
Sheep no. Bronchoalveolar cellinstillation type
Total BAL cell count
(cells/ml lavage fluid) at:
% BAL cells
PKH26 at:
BAL cell proviral
DNA PCR by
lobe type
Lymph node proviral DNA PCR result
24 h p.i. 8 days p.i. 24 h p.i. 8 days p.i. Instilled Naı¨ve Tracheobronchial Mediastinal Popliteal
1680 Autologous 1.4  107 1.6  107 0.91 1.16 ND ND ND ND ND
W48 Autologous 2.5  106 2.0  106 1.18 0.95     
1103D Autologous ND 1.4  106 ND 1.38     
817D Autologous ND 5.8  105 ND 2.45     
O61 Heterologous 1.0  106 1.2  106 1.22 1.71     
1102D Heterologous ND 4.7  105 ND 2.48     
847D Heterologous ND 2.6  105 ND 2.38     
a PCRs were performed to detect VMV gag proviral DNA. p.i., postinstillation; ND, not done.
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the bronchoalveolar space into the body. We have previously
shown that a primary mechanism of respiratory transmission of
VMV likely involves the inhalation of cell-free VMV and sub-
sequent virus uptake in the lower lung (33). Therefore, it is
possible that the uptake of VMV by resident AMs and the
subsequent transfer of virus into the body represent an impor-
tant route of natural respiratory transmission.
The observation that heterologous VMV-infected AMs are
capable of transmitting VMV demonstrates for the first time
that VMV-infected cells originating from one sheep are capa-
ble of infecting another. This was demonstrated only after
lower lung instillation of infected cells, suggesting that the
upper respiratory tract is relatively insensitive to cell-associ-
ated VMV, as is the case for cell-free VMV (46). As the site of
particle deposition in the lung is related to particle size, with
larger particles (10 m) being preferentially deposited in the
FIG. 4. Representative images of BAL cells and lung tissue from sheep W48 after instillation of autologous VMV-infected PKH26-labeled BAL
cells into the lower lung. Cell nuclei were counterstained with SYBR green dye. (A) BAL cells demonstrating a PKH26 cell with AM-like
morphology 8 days postinstillation. (B) BAL cells demonstrating a PKH26 cell with AM-like morphology 24 h postinstillation. (C) A single
PKH26 cell (arrow) present within the alveolar region of the lung 8 days postinstillation. (D) High-power view of the PKH26 cell seen in panel
C. B, bronchiole; SM, submucosal gland; A, alveolar space.
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upper respiratory tract and only smaller particles (	5 m)
gaining access to the lower airways (20), it is likely that the
majority of inhaled AMs (with average diameters of around 25
m) would be deposited in the upper respiratory tract. How-
ever, as it has been demonstrated that a small percentage of
larger particles (20 to 30 m) may penetrate the peripheral
areas of the lung (13), it is possible that a small number of
inhaled AMs indeed reach the lower lung and subsequently
transmit infection. Given the high efficiency of infection fol-
lowing lung instillation of infected AMs demonstrated here, it
is possible that a relatively small number of infected AMs
could transmit infection. Therefore, the transmission of VMV
via the inhalation of infected AMs derived from VMV-infected
sheep may represent an additional mechanism of VMV respi-
ratory transmission. Furthermore, as VMV-infected AMs have
been identified in the lungs of sheep with no VMV-induced
lesions and/or no clinical signs (48), AM-associated virus trans-
mission may represent a mechanism of transmission during
early prelesional and preclinical maedi.
The tracking of fluorescently labeled VMV-infected BAL
cells after lower lung instillation failed to demonstrate the
migration of labeled cells from the bronchoalveolar space up to
8 days postinstillation. Evidence for a lack of cell migration
from the lung airspace to the draining lymph nodes was based
on two observations. First, labeled cells were not detected
within the lung interstitium or lymph nodes. Second, the per-
centages of positively labeled cells in BAL samples were sim-
ilar at both 24 h and 8 days postinstillation. The intensity and
distribution of the staining of labeled cells at both time points
were identical to those of the stained cells preinstillation; this
indicated that positive cells detected within the lung airspace
had not proliferated within the lung airspace or had been
phagocytosed by other resident macrophages. This, therefore,
allowed a direct comparison of positive cell counts between
samples from the 24-h and 8-day time points, which, given their
similarities, suggests that no migration from the airspace had
occurred between these two time points. However, we cannot
rule out the possibility that some labeled cells migrated imme-
diately (	24 h) after instillation, or that a small number of
labeled cells migrated to the lymph node but remained unde-
tected.
Analysis for VMV identified proviral DNA but not viral
protein within labeled cell populations, indicating a typical in
vivo-restricted pattern of replication (19, 22), and demon-
strated provirus within the tracheobronchial lymph nodes of
sheep 8 days after instillation of both autologous and heterol-
ogous VMV-infected AMs. Provirus was present in the drain-
ing lymph node at a time comparable to that of a previous
study of cell-free VMV transfer from skin to draining lymph
nodes, which detected VMV-infected cells within the lymph
node from 4 days postinfection, with maximum numbers seen
between days 7 and 14 (5). The lack of evidence for direct cell
migration of VMV-infected AMs to this lymph node suggests
that virus transport from AMs to the tracheobronchial lymph
node occurred via an intermediate route and not by direct cell
migration of VMV-infected AMs. There did not appear to be
any significant difference in the dynamics of virus transfer to
the lymph nodes following instillation of either autologous or
heterologous AMs, and this was consistent with our observa-
tion that, following instillation of either autologous or heter-
ologous VMV-infected AMs, viremia and seroconversion oc-
cur at similar time points.
Transfer of virus from AMs to the tracheobronchial lymph
node could occur in two ways. First, cell-free virus particles
may be released from infected AMs, gain access to the lung
interstitium, and travel directly via the afferent lymph to the
draining lymph node. Second, VMV may be transferred from
AMs to an intermediate cell type that subsequently migrates to
the lymph node. A previous study of initial VMV dissemina-
tion after intradermal inoculation suggested that of these two
possibilities, virus transfer via an intermediate cell type rather
than as free virus is most likely: an analysis of afferent lymph
draining the virus inoculation sites demonstrated that virus was
exclusively cell associated, with no evidence of cell-free VMV
within lymph plasma (36). Furthermore, these VMV-positive
cells were shown to be afferent lymph DCs, suggesting that
respiratory tract DCs (RTDCs), which are found adjacent to
airways in high numbers (32), play a similar role in virus trans-
fer in the lung.
Both of these mechanisms would require the AMs to be
productively infected. The present study found evidence for
VMV gag, rev, and env transcript production in AMs following
free virus administration and provirus DNA in ex vivo-infected
AMs. In contrast, no virus protein could be detected by im-
munocytochemistry in either case, indicating that the virus in
AMs exhibited a typical in vivo-restricted pattern of replication
(22). However, due to a relative lack of sensitivity of the im-
munocytochemical technique, a small but significant number of
AMs may have been productively infected but remained un-
detected.
Interestingly, PCR analysis of in vivo-infected AMs detected
two populations of env gene transcripts generated by alterna-
tive splicing, whereas only the smaller env gene transcript was
detected in in vitro-infected OSCs. As the two env transcripts
differed by an insert 5 to the start of translation, the functional
significance of this alternative splicing event is unclear, as it
would be expected to have no effect on the structure of the
translated protein. However, the absence of the larger env
transcripts in productively infected OSCs indicates that in
these cells at least, the additional 45-bp insert is not required
for productive virus replication.
We hypothesized that VMV induces inflammatory responses
during initial infection, which subsequently would enhance vi-
rus uptake, either by the recruitment of VMV target cells, e.g.,
RTDCs, or by dysregulation of cytokine gene expression and
subsequent enhancement of VMV replication. Therefore, a
detailed analysis of lung inflammatory responses during early
infection with VMV strain EV1 was undertaken. Up-regula-
tion of AM GM-CSF mRNA expression was observed 7 days
after endoscopic instillation of VMV. This finding is consistent
with those of previous studies of naturally infected sheep lungs,
which demonstrated up-regulation of AM GM-CSF expression
in combination with up-regulation of other proinflammatory
cytokines and/or observable lung inflammation (29, 50). AM
IL-8 mRNA expression also was increased in virus-treated lung
lobes compared to that of untreated lung lobes but not com-
pared to that of mock-treated lobes, suggesting that the IL-8
response either was due to the BAL procedure or was induced
by components of the tissue culture medium of virus and mock
virus instillates. No changes in AM expression of other proin-
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flammatory cytokines were observed in this study, and with the
exception of an increase in bronchoalveolar lymphocyte pop-
ulations, analysis of lung tissue failed to demonstrate evidence
of lung inflammation. This is in contrast to two previous re-
ports of endoscopic instillation of VMV, which identified ex-
tensive inflammatory changes in virus-treated lung lobes after
11 days postinfection (17, 42). However, in these studies,
higher doses of a different strain of virus were used and the
sheep were of a different breed, each of which could influence
the degree of inflammatory response.
The observations in this study suggest that up-regulation of
AM GM-CSF mRNA expression was a specific effect of VMV
infection and was not due to the BAL procedure or the tissue
culture medium and was not secondary to a generalized in-
flammatory response. Furthermore, as virus infection after the
instillation of cell-free VMV strain EV1 into the lower lung is
known to be highly efficient (33), these results suggest that a
generalized inflammatory response is not essential for VMV
uptake in the lung. The mechanism(s) by which VMV up-
regulates AM GM-CSF expression in the absence of inflam-
mation is unclear, although interestingly, up-regulation of this
cytokine has been demonstrated in in vitro-cultured AMs in
response to inactivated VMV, suggesting that the interaction
between virus components and cell surface receptors is suffi-
cient for GM-CSF induction (49).
The specific increase in bronchoalveloar lymphocyte num-
bers following VMV instillation is consistent with findings of
previous experimental infection studies (2, 8) and, as lympho-
cyte infiltration is a characteristic of lymphoid interstitial pneu-
monia, may represent the early stages of VMV-induced pneu-
monia. How this lymphocyte recruitment is mediated is
unclear, but GM-CSF may be involved. It is known that local
T-cell responses within the lung are down-regulated by resi-
dent AMs (43, 45) and that GM-CSF is capable of abrogating
this immunosuppressive activity (3). Therefore, local GM-CSF
production by AMs may result in increased T-cell responses
within the bronchoalveolar space, with a resultant increase in
lymphocyte numbers. This would be consistent with the obser-
vation that GM-CSF appears to be a key driver in lung lesion
development in naturally infected sheep (49, 50).
In addition to playing a potential role in the pathogenesis of
lymphoid interstitial pneumonia, up-regulation of GM-CSF
expression by AMs in the early stages of infection also may
have implications regarding the initial uptake of VMV in the
lung. First, it has been demonstrated that GM-CSF enhances
VMV replication in monocyte-derived macrophages in vitro
(50). If a similar enhancement occurs in pulmonary macro-
phages, this could result in increased virus levels within the
lung and subsequently may increase virus uptake. Second, as
previously discussed, virus uptake from the lung airspace is
likely to involve RTDCs. Under steady-state conditions, AMs
maintain RTDCs in a down-modulated state (24). Treatment
with GM-CSF has been shown to inhibit this immunosuppres-
sive activity (3, 4). In addition, GM-CSF has been shown to
directly up-regulate the antigen-presenting activity of RTDCs
(1, 10) and also has been implicated in RTDC recruitment (44,
47). Therefore, the up-regulation of GM-CSF expression in
AMs may result in the switching of RTDCs toward a more
activated phenotype and also recruit RTDCs toward virus-
infected AMs, potentially enhancing RTDC uptake of virus
within the lung.
Furthermore, it is known that cellular interactions between
DCs and CD4 T cells within the draining lymph nodes are
crucial for VMV transfer from DCs to macrophages, which are
thought to be the main disseminator of VMV around the body
(16). Therefore, increased activation of RTDCs may result in
increased DC-CD4 T-cell interactions within the lymph
nodes with the subsequent enhancement of virus transfer to
macrophages. This may in turn lead to increased viral dissem-
ination throughout the body.
In conclusion, this study has demonstrated that resident AM
populations within the lung are capable of the uptake of cell-
free VMV and that this results in a specific up-regulation of
AM GM-CSF expression, which may in turn facilitate virus
uptake in the lower lung. Infected AMs were shown to be
capable of transmitting virus from the lower lung airspace, but
not from the upper respiratory tract, into the body. Further-
more, this transfer of virus did not appear to be mediated by
direct cell migration but appeared to involve an intermediate
route.
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